Navigation Links
Cephalon Reports Another Strong Quarter
Date:10/28/2008

" then "Webcast." The conference call will be archived and available to investors for one week after the call.

About Cephalon, Inc.

Founded in 1987, Cephalon, Inc. is an international biopharmaceutical company dedicated to the discovery, development and commercialization of innovative products in four core therapeutic areas: central nervous system, pain, oncology and addiction. A member of the Fortune 1000, Cephalon currently employs approximately 3,000 people in the United States and Europe. U.S. sites include the company's headquarters in Frazer, Pennsylvania, and offices, laboratories or manufacturing facilities in West Chester, Pennsylvania, Salt Lake City, Utah, and suburban Minneapolis, Minnesota. The company's European headquarters are located in Maisons-Alfort, France.

The company's proprietary products in the United States include: AMRIX, TREANDA, FENTORA(R) (fentanyl buccal tablet) [C-II], PROVIGIL(R) (modafinil) Tablets [C-IV], TRISENOX(R) (arsenic trioxide) injection, VIVITROL(R) (naltrexone for extended-release injectable suspension), GABITRIL(R) (tiagabine hydrochloride), NUVIGIL(TM) (armodafinil) Tablets [C-IV] and ACTIQ(R) (oral transmucosal fentanyl citrate) [C-II]. The company also markets numerous products internationally. Full prescribing information on its U.S. products is available at http://www.cephalon.com or by calling 1-800-896-5855.

In addition to historical facts or statements of current condition, this press release may contain forward-looking statements. Forward-looking statements provide Cephalon's current expectations or forecasts of future events. These may include statements regarding anticipated scientific progress on its research programs; development of potential pharmaceutical products; interpretation of clinical results; prospects for regulatory approval; manufacturing development and capabilities; market prospects for its products; characterization
'/>"/>

SOURCE Cephalon, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19

Related biology technology :

1. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
2. Cephalon, Inc. Announces Agreement to Acquire AMRIX, A Once-Daily Extended-Release Muscle Relaxant
3. Cephalon Reinforces Important Prescribing and Dosing Information for FENTORA
4. Cephalon Submits New Drug Application for TREANDA for the Treatment of Chronic Lymphocytic Leukemia
5. Cephalon Quarterly Conference Call Invitation
6. Cephalon Announces Strong Third Quarter Financial Results
7. Cephalon Submits Supplemental New Drug Application for FENTORA
8. Cephalon Submits New Drug Application for TREANDA for the Treatment of Patients with Relapsed Indolent Non-Hodgkins Lymphoma
9. Cephalon Presentation Slides for the 26th Annual JPMorgan Healthcare Conference Now Available
10. Cephalons EFFENTORA Receives Positive Opinion from European Regulatory Authorities for the Management of Breakthrough Cancer Pain
11. Cephalon Provides Update on Regulatory Status of the FENTORA Supplemental New Drug Application
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2014)... Sept. 23, 2014 /PRNewswire/ - Portage Biotech Inc. ("Portage" ... PBT.U), is pleased to announce that its wholly ... two more  consultants to its team for further ... a new proprietary cell permeable peptide platform technology ... cargo into the eye. Ms. ...
(Date:9/23/2014)... Mass. (PRWEB) September 23, 2014 Cambridge ... by Semantic Web technology, was named in the recent ... Gartner, Inc. , The report details key insights ... , According to Gartner analysts Michael Shanler and ... accelerate innovation activities, expose complex relationships with scientific stakeholders, ...
(Date:9/23/2014)... , September 23, 2014 ... System Transfer     Devices  (CSTD) for ... with Taiwanese distributor MedFront Medical Technology Corporation.  Equashield,s leading CSTD ... Taiwan , China ... company continues to expand globally, and throughout the ...
(Date:9/23/2014)... 23, 2014 Marktech Optoelectronics has introduced ... violet emitters in the 280 nm wavelength range. This ... which range from 280nm to 405nm. These new devices ... as well as curing. Mark Campito, Marktech’s CEO states ... interest to manufacturers is that we offer it in ...
Breaking Biology Technology:Portage Announces New Consultants for its PPL-003 Development Programs 2Portage Announces New Consultants for its PPL-003 Development Programs 3Portage Announces New Consultants for its PPL-003 Development Programs 4Cambridge Semantics Identified in Gartner’s ‘Hype Cycle for Life Sciences 2014’ Report 2Equashield Enters Taiwan Following Expansion to Australia, Japan, China 2Marktech Introduces its New Line of Deep UV Emitters 2
... N.J. , June 16 Soligenix, Inc. (OTC Bulletin ... today that it has entered into common stock purchase agreements with ... Soligenix,s North American commercial partner, Sigma-Tau Pharmaceuticals, Inc., participated in this ... , ...
... ... has released two new boards based on the Altera Stratix® IV 820 devices. These ... and prototype their own products. , ... Richardson, Texas (PRWEB) June 16, 2010 -- IRIS Technologies Inc. ( www.iris-technologies.net ...
... ... METTLER TOLEDO has announced the release of iC ... chemical reactions by automatically developing a kinetic model that describes the ... reaction. The kinetic model can be used to simulate the effect ...
Cached Biology Technology:Soligenix Announces Private Equity Financing of $5.16 Million With Its Partner Sigma-Tau and Other Institutional Investors 2Soligenix Announces Private Equity Financing of $5.16 Million With Its Partner Sigma-Tau and Other Institutional Investors 3Soligenix Announces Private Equity Financing of $5.16 Million With Its Partner Sigma-Tau and Other Institutional Investors 4IRIS Technologies Inc. Launches Two New Stratix IV FPGA-Based Boards 2IRIS Technologies Inc. Launches Two New Stratix IV FPGA-Based Boards 3A Faster Way to Understand and Optimize your Chemistry 2
(Date:9/23/2014)... of Health will award funds to support the next ... to improve ways of predicting drug safety and effectiveness. ... 3-D human tissue chips and combine them into an ... the human body. Led by the National Center for ... institutions at $17 million in 2014 with additional support ...
(Date:9/23/2014)... on insects to predict how climate change will affect ... for the first time that insects, fear of their ... they grow. , "In other words, it,s less about ... shape the growth, survival and distribution of insects." says ... Arctic postdoctoral researcher at Dartmouth. , The study ...
(Date:9/23/2014)... scientists who are fighting a cyberwar against cancer finds ... powerful ally. , "Recent research has found that cancer ... system, and we studied the interplay between cancer and ... the tables on cancer," said Rice University,s Eshel Ben-Jacob, ... Early Edition of the Proceedings of the National ...
Breaking Biology News(10 mins):NIH funds next phase of Tissue Chip for Drug Screening program 2NIH funds next phase of Tissue Chip for Drug Screening program 3NIH funds next phase of Tissue Chip for Drug Screening program 4Insects' fear limits boost from climate change, Dartmouth study shows 2Immune system is key ally in cyberwar against cancer 2Immune system is key ally in cyberwar against cancer 3
... A component of DNA that can both stimulate ... may hold hope for treating cancer and infection, Medical ... of CpG increase inflammation, part of the body,s way ... increasing expression of the enzyme indoleamine 2,3 dioxygenase, or ...
... A new study by researchers at Princeton University,s Woodrow ... that global climate change may lead to the retreat ... States, which could create unprecedented ecological restoration opportunities across ... time, global warming may enable other invasive plants to ...
... a surprising link between brain iron levels and ... from autism to major depression., Appearing in the ... this week, the study by Randy Blakely, ... a powerful in silico approach for discovering novel ...
Cached Biology News:DNA component can stimulate and suppress the immune response 2Climate change's impact on invasive plants in Western US may create restoration opportunities 2Climate change's impact on invasive plants in Western US may create restoration opportunities 3Climate change's impact on invasive plants in Western US may create restoration opportunities 4Researchers iron out new role for serotonin 2
... is the simplest, easiest-to-use system ever for ... handling capabilities,into their labs, or groups in ... applications on a separate instrument. Plate-handling is ... even when you have thousands of samples., ...
... Safe Deposit Service ECACC is able to accept ... cGMP for cryo-storage. The cell lines must be ... been produced in accordance with the requirements of ... freedom from mycoplasma, bacteria or fungi. What are ...
... provides cost effective cell culture services for ... antibodies. Quality at a reasonable price is ... research or commercial product, we strive toward ... as roller bottles, hollow fiber, and bioreactor ...
... Cell Bank Service The Human Genetic ... Epstein-Barr Virus (EBV) immortalisation of human peripheral ... of lymphoblastoid cell lines (LCLs). These cell ... and expandable source of genomic DNA and ...
Biology Products: